In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alveolus Inc.

Division of Merit Medical Systems Inc.
www.alveolus.com

Latest From Alveolus Inc.

The Lure of Late-Stage Device Investing

In 2006, the number of late-stage private equity deals in the medical device sector is up significantly from 2005. At the IN3 East medtech conference in October, a lively panel of venture capital investors from Galen Partners, 3i, Matignon Technologies and OrbiMed Advisors discussed why this is so, and the risks, benefits and models for late-stage investing.
Medical Device Business Strategies

Matignon Launches Major New European Device Fund

Europe has a remarkable tradition of clinical thought leaders who develop major new medical device technologies. Yet European device company start-up activity lags far behind the rate of clinical breakthroughs. There are several reasons for this, including the dearth of European venture capital willing to back these start-ups. Matignon Technologies sees this gap in financing of European device start-ups as an opportunity, and has just launched one of the largest European funds dedicated primarily to medical technology.
Medical Device Europe

US Markets for Nonvascular Stents

Lately, drug-eluting stents have downright monopolized all discussions of new stent technology, but there's a whole world of stenting outside of the interventional cardiology suite, and some of these clinical applications represent healthy markets for small companies. According to a report published in June by the Medtech Insight division of Windhover Information, "US Markets for Nonvascular Stents," sales of stents in several non-cardiology niche markets totaled approximately $152 million in 2005, a year in which stents were used in approximately 491,000 nonvascular endoluminal recanalization procedures. Overall, sales of these products are expected to grow at an annual compound rate of almost 3%, reaching approximately $174 million in the year 2010.
Medical Device

Alveolus Inc.

Alveolus Inc. is focused on stenting obstructed airways and other nonvascular lumens with a removable self-expanding metal stent that can be placed with direct visualization. The company believes that in addition to improving the quality of life for terminally ill cancer patients, its products can potentially be used as temporary, minimally invasive treatments in many diseases characterized by benign lumenal obstructions.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Gastrointestinal
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merit Medical Systems Inc.
  • Senior Management
  • David Chazanovitz, Pres. & CEO
    Mike Reid, CFO
  • Contact Info
  • Alveolus Inc.
    Phone: (704) 926-4837
    9013 Perimeter Woods
    Ste. A
    Charlotte, NC 28216
    USA
UsernamePublicRestriction

Register